Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.
暂无分享,去创建一个
[1] P. Ridker,et al. A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.
[2] P. Elwood,et al. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. , 1991, Circulation.
[3] S. Thompson,et al. HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.
[4] E. B. Smith,et al. Fate of fibrinogen in human arterial intima. , 1990, Arteriosclerosis.
[5] D. Slosman,et al. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism , 1991, The Lancet.
[6] W. Willett,et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.
[7] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[8] C. Francis,et al. A Molecular Model of Plasmic Degradation of Crosslinked Fibrin , 1982, Seminars in thrombosis and hemostasis.
[9] J. Manson,et al. Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor , 1992, Circulation.
[10] A. Rumley,et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease , 1993, The Lancet.
[11] D. Rylatt,et al. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems , 1985, British journal of haematology.
[12] J. Erikssen,et al. Blood Platelet Count and Function Are Related to Total and Cardiovascular Death in Apparently Healthy Men , 1991, Circulation.
[13] J. T. ten Cate,et al. A Comparative Analysis of D-Dimer Assays in Patients with Clinically Suspected Pulmonary Embolism , 1993, Thrombosis and Haemostasis.
[14] R. Bick. The Clinical Significance of Fibrinogen Degradation Products , 1982, Seminars in thrombosis and hemostasis.
[15] P. Ridker,et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.
[16] P. Mombaerts,et al. Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis , 1987, Thrombosis and Haemostasis.
[17] J. Cooper,et al. Antithrombin III and arterial disease , 1992, The Lancet.
[18] J. Schapiro,et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.
[19] J. Loscalzo,et al. Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. , 1988, American heart journal.
[20] P. de Moerloose,et al. Measurement of plasma D-dimer for diagnosis of deep venous thrombosis. , 1989, American journal of clinical pathology.
[21] P. Ridker. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease , 1992 .
[22] M. Blombäck,et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.
[23] J. Manson,et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.
[24] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[25] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[26] P. Ridker,et al. Hemostatic risk factors for coronary heart disease. , 1991, Circulation.